Unproven Autism Drug Prescriptions Surged Following White House Briefing

An unproven autism treatment experienced an explosive surge in pediatric prescriptions across the United States following a high-profile White House briefing held on September 22, 2025, according to peer-reviewed data published in JAMA Network Open and The Lancet. During the event, President Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and FDA Commissioner Marty Makary discussed leucovorin—a drug primarily used to counteract the toxic side effects of chemotherapy—as a promising therapy for autism. The announcement occurred without new clinical trial evidence or standard Food and Drug Administration regulatory review, triggering immediate shifts in national prescribing patterns and raising significant questions for clinical practice.

• Pediatric prescriptions for leucovorin surged by more than 2,000% following the federal announcements, climbing from a baseline of 34 per 100,000 outpatient encounters to over 835 per 100,000.
• Emergency department administration of acetaminophen to pregnant patients declined by approximately 10% following warnings linking the analgesic to autism in children.
• Researchers analyzing electronic health records from over 300 million patients emphasized that public messaging from government officials can dramatically alter real-world medical practices before large clinical trials establish whether a treatment is truly safe and effective.

National Electronic Health Records Quantify Prescription Spikes

To measure the tangible impact of the September 22, 2025 federal briefing, independent researchers turned to massive national datasets. A study published on May 18, 2026, in JAMA Network Open by Joshua Rothman, MD, and colleagues utilized Epic Cosmos electronic health record data. The analysis encompassed more than 300 million patient records across 1,800 hospitals and 41,500 clinics in all 50 states, tracking 838,801 children with autism over 11.9 million outpatient encounters between January 2023 and January 2026.

For roughly two years, prescription rates for leucovorin remained stable at approximately 34 prescriptions per 100,000 outpatient encounters. An initial upward drift began in February 2025, driven by a CBS Evening News segment featuring a family reporting dramatic language improvements in their autistic child. Prescriptions reached 335 per 100,000 encounters by August 2025. Following the White House briefing in September 2025, the rate escalated past 835 per 100,000 encounters by November 2025, representing an increase exceeding 2,000% above the two-year baseline.

“Families of children with autism are often searching for therapies that might improve communication and quality of life, especially when treatment options are limited,” said lead author Joshua Rothman, MD, clinical assistant professor of pediatrics at UC San Diego School of Medicine. “What this study shows is how quickly information shared through news coverage, social media, and public figures can influence real-world prescribing patterns, even before large clinical trials establish whether a treatment is truly safe and effective.”

Parallel Declines in Prenatal Acetaminophen Administration

The White House event also addressed prenatal medication use, specifically warning pregnant women to limit acetaminophen—the active ingredient in Tylenol—claiming it was linked to autism in children. Prescription shifts were evaluated in a related study led by JS Faust and ML Barnett, issued in The Lancet in March 2026, which looked at a separate Epic dataset comprising 88,857 emergency department visits by pregnant individuals and 853,216 visits by non-pregnant patients from September 22 to December 7, 2025.

Emergency departments administered acetaminophen to pregnant patients roughly 10% less often than before during this window. Researchers noted no comparable shifts in several comparison drugs, isolating the change as a direct reaction to official public messaging. This drop occurred despite prior epidemiological data. Evaluating 2.48 million children born in Sweden between 1995 and 2019, a sibling-controlled cohort study published in JAMA in 2024 uncovered no elevated threat of attention-deficit/hyperactivity disorder, autism, or intellectual disability when comparing brother-and-sister pairs with and without prenatal exposure to acetaminophen.

Regarding leucovorin, scientists have investigated the drug because some children with autism appear to have a problem called cerebral folate deficiency, a condition where their brains may not get enough folate. Nevertheless, certain specialists in autism cautioned that clinical backing for leucovorin remains preliminary and mandates more extensive investigations.

As academic medical centers continue evaluating the long-term neurological and behavioral outcomes associated with off-label drug utilization, ongoing surveillance of electronic health records will remain vital for measuring how political and media messaging translates into clinical reality. Clinicians navigating patient inquiries regarding unapproved interventions must balance family urgency against rigorous methodological standards.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.